Digital therapeutics company Pear Therapeutics has raised $64m in a series C funding round led by investment firm Temasek. The new fund will invest in companies that develop and commercialise novel treatments for diseases such as cancer, diabetes, cardiovascular disease, Alzheimer’s disease and Parkinson’s. It will also allow the corporation to add to its two FDA-approved prescription digital therapeutics through extra funding for its clinical-stage pipeline. Finally, the extra finance puts Pear Therapeutics in a position to make asset acquisitions that could diversify its products.
Digital therapeutics company Pear Therapeutics has raised $64m in a series C funding round led by investment firm Temasek. The cash injection will be used to market the company's suite of software-based disease treatments, called reSET, internationally. It will also allow the corporation to add to its two FDA-approved prescription digital therapeutics through extra funding for its clinical-stage pipeline. Finally, the extra finance puts Pear Therapeutics in a position to make asset acquisitions that could diversify its products.